Glycine/NMDA receptor antagonists as potential CNS therapeutic agents: ACEA-1021 and related compounds

Current Topics in Medicinal Chemistry

Volumn 6, Issue 7, 2006, Pages 651-662

  Cai, Sui Xiong ^a  

^a EpiCept Corporation   (United States)

Author keywords

6,7 dinitro QX (DNQX); Benzazepine derivatives; CNS drugs; GV150526; NMDA receptors; Xenopus Oocytes

Indexed keywords

2,3 QUINOXALINEDIONE DERIVATIVE; 5 CYANO 6,7 DICHLORO 2,3 QUINOXALINEDIONE; 5 CYANO 7 CHLORO 6 METHYL 2,3 QUINOXALINEDIONE; 5 NITRO 2,3 QUINOXALINEDIONE; 5 NITRO 6 BROMO 7 CHLORO 2,3 QUINOXALINEDIONE; 5 NITRO 6 CHLORO 7 BROMO 2,3 QUINOXALINEDIONE; 5 NITRO 6,7 DIBROMO 2,3 QUINOXALINEDIONE; 6 CHLORO 7 METHYL 5 NITRO 2,3 QUINOXALINEDIONE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6,7 DICHLORO 2,3 QUINOXALINEDIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 6,7 DIMETHYL 5 NITRO 2,3 QUINOXALINEDIONE; 7 BROMO 5 (N OXY)AZA 2,3 QUINOXALINEDIONE; 7 BROMO 6 METHYL 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 5 (N OXY)AZA 2,3 QUINOXALINEDIONE; 7 CHLORO 5 CYANO 2,3 QUINOXALINEDIONE; 7 CHLORO 6 METHYL 5 NITRO 2,3 QUINOXALINEDIONE; 7 METHYL 5 (N OXY)AZA 2,3 QUINOXALINEDIONE; 7 NITRO 5 (N OXY)AZA 2,3 QUINOXALINEDIONE; ACEA 1416; BENZAZEPINE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; CHLORO 6 METHYL NITRO 2,3 QUINOXALINEDIONE; GAVESTINEL; GLUTAMIC ACID; GLYCINE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUINOLIN 2(1H)ONE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; CONVULSION; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IN VIVO STUDY; NEUROPROTECTION; NONHUMAN; PAIN; RECEPTOR INTRINSIC ACTIVITY; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; TRAUMATIC BRAIN INJURY;

ANIMALS; CENTRAL NERVOUS SYSTEM; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; QUINOXALINES; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646586668     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802606776894465     Document Type: Review

References (87)

1. a Monaghan, D. T.; Bridges, R. J.; Cotman, C. W. The Excitatory Amino Acid Receptors: Their Classes, Pharmacology, and Distinct Properties in the Function of the Central Nervous System. Annu. Rev. Pharmacol. Toxicol. 1989, 29, 365-402.
2. b Kew, J. N. C.; Kemp, J. A. Ionotropic and Metabotropic Glutamate Receptor Structure and Pharmacology. Psychopharmacology 2005, 179, 4-29.
3. Seeberg, P. H. The Molecular Biology of Mammalian Glutamate Receptor Channels. Annu. Rev. Neurosci. 1993, 16, 359-365.
4. Knopfel, T.; Kuhn, R.; Allgeier, H. Metabotropic Glutamate Receptors: Novel Targets for Drug Development. J. Med. Chem. 1995, 38, 1417-1426.
5. Meldrum, B.; Garthwaite, J. Excitatory Amino Acid Neurotoxicity and Neurodegenerative Disease. Trends Pharmacol. Sci. 1990, 11, 379-387.
6. Gasic, G. P.; Hollmann, M. Molecular Neurobiology of Glutamate Receptors. Annu. Rev. Physiol. 1992, 54, 507-36.
7. Rothman, S. M.; Olney, J. W. Excitotoxicity and the NMDA Receptor - Still Lethal after Eight Years. Trends Neurosci. 1995, 18, 57-58.
8. Doble, A. Excitatory Amino Acid Receptors and Neurodegeneration. Therapie 1995, 50, 319-337.
9. Molinuevo, J. L.; Llado, A.; Rami, L. Memantine: Targeting Glutamate Excitotoxicity in Alzheimer's Disease and other Dementias. Am. J. Alzheimers Dis. Other Demen. 2005, 20, 77-85.
10. Coyle, J. T.; Tsai, G. The NMDA Receptor Glycine Modulatory Site: a Therapeutic Target for Improving Cognition and Reducing Negative Symptoms in Schizophrenia. Psychopharmacology 2004, 174, 32-38.
11. Johnson, J. W.; Ascher, P. Glycine Potentiates the NMDA Response in Cultured Mouse Brain Neurons. Nature 1987, 325, 529-531.
12. Leeson, P. D. Glycine-Site N-Methyl-D-aspartate Receptor Antagonists. In Drug Design for Neuroscience. Kozikowski, A. P. Ed. Raven Press, New York, 1993, Chapter 13, pp. 339-381.
13. Hargreaves, R. J.; Rigby, M.; Smith, D.; Hill, R. G.; Iversen, L. L. Competitive as well as Uncompetitive N-methyl-D-aspartate Receptor Antagonists Affect Cortical Neuronal Morphology and Cerebral Glucose Metabolism. Neurochem. Res. 1993, 18, 1263-1269.
14. Olney, J. W.; Labruyere, J.; Wang, G.; Wozniak, D. F.; Price, M. T.; Sesma, M. A. NMDA Antagonist Neurotoxicity: Mechanism and Prevention. Science 1991, 254, 1515-1518.
15. Hargreaves, R. J.; Rigby, M.; Smith, D.; Hill, R. G. Lack of Effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA Receptor Antagonist Acting at the Glycine Site, on Cerebral Glucose Metabolism and Cortical Neuronal Morphology. Br. J. Pharmacol. 1993, 110, 36-42.
16. Hawkinson, J. E.; Huber, K. R.; Sahota, P. S.; Hsu, H. H.; Weber, E.; Whitehouse, M. J. The N-methyl-D-aspartate (NMDA) Receptor Glycine Site Antagonist ACEA 1021 Does not Produce Pathological Changes in Rat Brain. Brain Res. 1997, 744, 227-234.
17. a Kemp, J. A.; Leeson, P. D. The Glycine Site of the NMDA Receptor - Five Years on. Trends Pharmacol. Sci. 1993, 14, 20-25.
18. b Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067.
19. c Dannhardt, G.; Kohl, B. K. The Glycine Site on the NMDA Receptor: Structure-activity Relationships and Possible Therapeutic Applications. Curr. Med. Chem. 1998, 5, 253-263.
20. (d) Cai, S. X. Glycine/NMDA Receptor Antagonists: Structure-Activity Relationships and Potential Therapeutic Application. In Frontiers of Biotechnology & Pharmaceuticals, Vol. 1. Zhao, Reiner & Chen, Eds.; Science Press, New York, 2000, pp 233-256.
21. (e) Jansen, M.; Dannhardt, G. Antagonists and Agonists at the Glycine Site of the NMDA Receptor for Therapeutic Interventions. Eur. J. Med. Chem. 2003, 38, 661-70.
22. Honore, T.; Davies, S. N.; Drejer, J.; Fletcher, E. J.; Jacobsen, P.; Lodge, D.; Dielsen, F. E. Quinoxalinediones: Potent Competitive Non-NMDA Glutamate Receptor Antagonists. Science 1988, 241, 701-703.
23. Birch, P. J.; Grossman, C. J.; Hayes, A. G. 6,7-Dinitro-quinoxaline-2,3-dione and 6-Nitro-7-cyano-quinoxaline-2,3-dione Antagonise Responses to NMDA in the Rat Spinal Cord via an Action at the Strychnine-insensitive Glycine Receptor. Eur. J. Pharmacol. 1988, 156, 177-180
24. Woodward, R. M.; Huettner, J. E.; Guastella, J.; Kenna, J. F. W.; Weber, E. In Vitro Pharmacology of ACEA-1021 and ACEA-1031: Systemically Active Quinoxalinediones with High Affinity and Selectivity for N-methyl-D-aspartate Receptor Glycine Sites. Mol. Pharmacol. 1995, 47, 568-581.
25. Warner, D. S.; Martin, H.; Ludwig, P.; McAllister, A.; Keana, J. F. W.; Weber, E. In Vivo Models of Cerebral Ischemia: Effects of Parenterally Administered NMDA Receptor Glycine Site Antagonists. J. Cereb. Blood Flow Metab. 1995, 158, 188-196.
26. Keana, J. F. W.; Kher, S. M.; Cai, S. X.; Dinsmore, C. M.; Glenn, A. G.; Guastella, J.; Huang, J. C.; Ilyin, V.; Lu, Y.; Mouser, P. L.; Woodward, R. M.; Weber, E. Synthesis and Structure-activity Relationships of Substituted 1,4-Dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) Receptor Glycine Sites and Non-NMDA Glutamate Receptors. J. Med. Chem. 1995, 38, 4367-4379.
27. Lufty, K.; Shen, K.-Z.; Kwon, I.-S.; Cai, S. X.; Woodward, R. M.; Keana, J. F. W.; Weber, E. Blockade of Morphine Tolerance by ACEA-1328, a Novel NMDA Receptor/Glycine Site Antagonist. Eur. J. Pharm. 1995, 273, 187-189.
28. Cai, S. X.; Kher, S. M.; Zhou, Z.-L.; Ilyin, V.I.; Espitia, S. A.; Tran, M.; Hawkinson, J. E.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Structure-activity Relationships of Alkyl- and Alkoxy-substituted 1,4-Dihydroquinoxaline-2,3-diones: Potent and Systemically Active Antagonists for the Glycine site of the NMDA Receptor. J. Med. Chem. 1997, 40, 730-738.
29. Ilyin, V. I.; Whittemore, E. R.; Tran, M.; Shen, K.-Z.; Cai, S. X.; Kher, S. M.; Keana, J. F. W.; Weber, E.; Woodward, R. M. Pharmacology of ACEA-1416: a Potent Systemically Active NMDA Receptor Glycine Site Antagonist. Eur. J. Pharmacol. 1996, 310, 107-114.
30. Hansch, C.; Bjorkroth, J. P.; Leo, A. Hydrophobicity and Central Nervous System Agents: on the Principle of Minimal Hydrophobicity in Drug Design. J. Pharm. Sci. 1987, 76, 663-687.
31. Cai, S. X.; Weber, E.; Keana, J. F. W.; Kher, S. Alkyl, Azido, Alkoxy, and Fluoro-substituted and Fused Quinoxalinediones and the Use Thereof as Glycine Receptor Antagonists. United States Patent 5,977, 107, November 2, 1999.
32. Zhou, Z.-L.; Kher, S. M.; Cai, S. X.; Whittemore, E. R.; Espitia, S. A.; Hawkinson, J. E.; Tran, M.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Synthesis and SAR of Novel Di- and Trisubstituted 1,4-Dihydroquinoxaline-2,3-diones Related to Licostinel (ACEA 1021) as NMDA/Glycine Site Antagonists. Bioorg. Med. Chem. 2003, 11, 1769-1780.
33. Cai, S. X.; Huang, J.-C.; Espitia, S. A.; Tran, M.; Ilyin, V. I.; Hawkinson, J. E.; Woodward, R. M.; Weber, E.; Keana, J. F. W. 5- (N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, Systemically Active and Broad Spectrum Antagonists for NMDA/glycine, AMPA, and Kainate receptors. J. Med. Chem, 1997, 40, 3679-3686.
34. Lutfy, K.; Cai, S. X.; Woodward, R. M.; Weber, E. Antinociceptive Effects of NMDA and Non-NMDA Receptor Antagonists in the Tail Flick Test in Mice. Pain 1997, 70, 31-40.
35. Cai, S. X.; Weber, E.; Keana, J. F. W. 8-Aza, 6-Aza and 6,8-Diaza-1,4-dihydroquinoxaline-2,3-diones and the Use Thereof as Antagonists for the Glycine/NMDA Receptor. United States Patent 5,620,978, April 15, 1997.
36. Nagata R.; Tanno, N.; Kodo, T.; Ae, N.; Yamaguchi, H.; Nishimura, T.; Antoku, F.; Tatsuno, T.; Kato, T.; Tanaka, Y.; Nakamura, M. Tricyclic Quinoxalinediones: 5,6-Dihydro-1H-pyrrolo [1,2,3-de]quinoxaline-2,3-diones and 6,7-Dihydro-1H,5H-pyrido [1,2,3-de]quinoxaline-2,3-diones as Potent Antagonists for the Glycine Binding Site of the NMDA Receptor. J. Med. Chem. 1994, 37, 3956-3968.
37. Ohtani, K.; Tanaka, H.; Yasuda, H.; Maruoka, Y.; Kawabe, A.; Nakamura, M. Blocking the Glycine-binding site of NMDA Receptors Prevents the Progression of Ischemic Pathology Induced by Bilateral Carotid Artery Occlusion in Spontaneously Hypertensive Rats. Brain Res. 2000, 871, 311-318.
38. Auberson, Y. P.; Bischoff, S.; Moretti, R.; Schmutz, M.; Veenstra, S. J. 5-Aminomethylquinoxaline-2,3-diones. Part I: A Novel Class of AMPA Receptor Antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 65-70.
39. Auberson, Y. P.; Acklin, P.; Allgeier, H.; Biollaz, M.; Bischoff, S.; Ofner, S.; Veenstra, S. J. 5-Aminomethylquinoxaline-2,3-diones. Part II: N-Aryl Derivatives as Novel NMDA/glycine and AMPA Antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 71-74.
40. Nikam, S. S.; Cordon, J. J.; Ortwine, D. F.; Heimbach, T. H.; Blackburn, A. C.; Vartanian, M. G.; Nelson, C. B.; Schwarz, R. D.; Boxer, P. A.; Rafferty, M. F. Design and Synthesis of Novel Quinoxaline-2,3-dione AMPA/ GlyN Receptor Antagonists: Amino Acid Derivatives. J. Med. Chem. 1999, 42, 2266-2271.
41. Acklin, P.; Allgeier, H.; Auberson, Y. P.; Bischoff, S.; Ofner, S.; Sauer, D.; Schmutz, M. 5-Aminomethylquinoxaline-2,3-diones, Part III: Arylamide Derivatives as Highly Potent and Selective Glycine-site NMDA Receptor Antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 493-498.
42. Fray, M. J.; Bull, D. J.; Carr, C. L.; Gautier, E. C.; Mowbray, C. E.; Stobie, A. Structure-activity Relationships of 1,4-Dihydro-(1H,4H)-quinoxaline-2,3-diones as N-methyl-D-aspartate (Glycine Site) Receptor Antagonists. 1. Heterocyclic Substituted 5-Alkyl Derivatives. J. Med. Chem. 2001, 44, 1951-1962.
43. Webster, R.; Cole, S.; Gedge, J.; Roffey, S.; Walker, D.; Wild, W. Pharmacokinetics and Disposition of a Novel NMDA Glycine Site Antagonist (UK-240,455) in Rats, Dogs and Man. Xenobiotica 2003, 33, 541-560.
44. Cai, S. X. Weber, E.; Keana, J. F. W. Glycine Receptor Antagonists Pharmacophore, United States. Patent 5,597,922, January 28, 1997.
45. Cai, S. X.; Zbou, Z.-L.; Huang, J.-C.; Whittemore, E. R.; Egbuwoku, Z. O.; Lu, Y. Hawkinson, J. E.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Synthesis and Structure-activity Relationships of 1,2,3,4-Tetrahydroquinoline-2,3,4-trione 3-Oximes: Novel and Highly Potent Antagonists for NMDA Receptor Glycine Site. J. Med. Chem. 1996, 39, 3248-3255.
46. Cai, S. X.; Zhou, Z.-L.; Huang, J.-C. Whittemore, E. R.; Egbuwoku, Z. O.; Hawkinson, J. E.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Structure-activity Relationships of 4-Hydroxy-3-nitroquinolin-2(1H)-ones as Novel Antagonists at the Glycine Site of N-methyl-D-aspartate Receptors. J. Med. Chem. 1996, 39, 4682-4686.
47. Kulagowski, J. J.; Baker, R.; Curtis, N. R.; Leeson, P. D.; Mawer, I. M.; Moseley, A. M.; Ridgill, M. P.; Rowley, M.; Stansfield, I.; Foster, A. G.; Grimwood, S.; Hill, R. G.; Kemp, J. A.; Marshall, G. R.; Saywell, K. L.; Tricklebank, M. D. 3′-(Arylmethyl)- and 3′-(Aryloxy)-3-phenyl-4-hydroxyquinoline-2(1H)-ones: Orally Active Antagonists of the Glycine Site on the NMDA Receptor. J. Med. Chem. 1994, 37, 1402-1405.
48. Rowley, M.; Kulagowski, J. J.; Watt, A. P.; Rathbone, D.; Stevenson, G. I.; Carling, R. W.; Baker, R.; Marshall, G. R.; Kemp, J. A.; Foster, A. G.; Grimwood, S.; Hargreaves, R.; Hurley, C.; Saywell, K. L.; Tricklebank, M. D.; Curtis, N. R.; Leeson, P. D.; Mawer, I. M.; Moseley, A. M.; Ridgill, M. P.; Stansfield, I.; Hill, R. G. Effect of Plasma Protein Binding on In Vivo Activity and Brain Penetration of Glycine/ NMDA Receptor Antagonists. J. Med. Chem. 1997, 40, 4053-4068.
49. Zhou, Z.-L.; Navratil, J. M.; Cai, S. X.; Whittemore, E. R.; Espitia, S. A.; Hawkinson, J. E.; Tran, M.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Synthesis and SAR of 5-, 6-, 7- and 8-Aza Analogs of 3-Aryl-4-hydroxyquinolin-2(1H)-one as NMDA/Glycine Site Antagonists. Bioorg. Med. Chem. 2001, 9, 2061-2071.
50. Swartz, K. J.; Koroshetz, W. J.; Rees, A. H.; Huettner, J. E. Competitive Antagonism of Glutamate Receptor Channels by Substituted Benzazepines in Cultured Cortical Neurons. Mol. Pharmacol. 1992, 41, 1130-1141.
51. Guzikowski, A. P.; Cai, S. X.; Espitia, S. A.; Hawkinson, J. E.; Huettner, J. E.; Nogales, D. F.; Tran, M.; Woodward, R. M.; Weber, E.; Keana J. F. W. Analogs of 3-Hydroxy-1H-1-benzazepine-2,5-dione: Structure-activity Relationship at N-methyl-D-aspartate Receptor Glycine Sites. J. Med. Chem. 1996, 39, 4642-4653.
52. Guzikowski, A. P.; Whittemore, E. R.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Synthesis of Racemic 6,7,8,9-Tetrahydro-3-hydroxy-1H-1-benzazepine-2,5-diones as Antagonists of N-methyl-D-aspartate (NMDA) and (α-amino-3-hydroxy-5-methylisoxazole-4-propionic Acid (AMPA) Receptors. J. Med. Chem. 1997, 40, 2424-2429.
53. Petty, M. A.; Weintraub, P. M.; Maynard, K. I. ACEA 1021: Flip or Flop? CNS Drug Rev. 2004, 10, 337-348.
54. Newell, D. W.; Barth, A.; Malouf, A. T. Glycine Site NMDA Receptor Antagonists Provide Protection Against Ischemia-induced Neuronal Damage in Hippocampal Slice Cultures. Brain Res. 1995, 675, 38-44.
55. Pearlstein, R. D.; Beirne, J. P.; Massey, G. W.; Warner, D. S. Neuroprotective Effects of NMDA Receptor Glycine Recognition Site Antagonism: Dependence on Glycine Concentration. J. Neurochem. 1998, 70, 2012-2019.
56. 125I-MK-801 Binding after Subdural Hematoma in the Rat: an In Vivo Autoradiographic Study. J. Neurosurg. 1996, 85, 655-661.
57. Tsuchida, E.; Bullock, R. The Effect of the Glycine Site-specific N-methyl-D-aspartate Antagonist ACEA1021 on Ischemic Brain Damage Caused by Acute Subdural Hematoma in the Rat. J. Neurotrauma 1995, 12, 279-288.
58. Matsumoto, R. R.; Nguyen, D.; Truong, D. D. Strychnine-insensitive Glycine Site Antagonists Attenuate a Cardiac Arrest-induced Movement Disorder. Eur. J. Pharmacol. 1995, 275, 117-123.
59. Takaoka, S.; Bart, R. D.; Pearlstein, R.; Brinkhous, A.; Warner, D. S. Neuroprotective Effect of NMDA Receptor Glycine Recognition Site Antagonism Persists when Brain Temperature Is Controlled. J. Cereb. Blood Flow Metab. 1997, 17, 161-167.
60. Sarhan, S.; Wettstein, J. G.; Maynard, K. I. Delayed Treatment with 5-Nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione, a Glycine Site N-methyl-D-aspartate Antagonist, Protects Against Permanent Middle Cerebral Artery Occlusion in Male Rats. Neurosci. Lett. 2003, 347, 147-150.
61. Petty, M. A.; Neumann-Haefelin, C.; Kalisch, J.; Sarhan, S.; Wettstein, J. G.; Juretschke, H. P. In Vivo Neuroprotective Effects of ACEA 1021 Confirmed by Magnetic Resonance Imaging in Ischemic Stroke. Eur. J. Pharmacol. 2003, 474, 53-62.
62. Auer, R. N. Structural Neurotoxicologic Investigation of the Gycine Antagonist 5-Nitro-6,7-dichloroquinoxalinedione (ACEA-1021). Neurotoxicology 1997, 18, 53-62.
63. Danysz, W.; Parsons, C. G.; Karcz-Kubicha, M.; Schwaier, A.; Popik, P.; Wedzony, K.; Lazarewicz, J.; Quack, G. GlycineB Antagonists as Potential Therapeutic Agents. Previous Hopes and Present Reality. Amino Acids 1998, 14, 235-239.
64. Kretschmer, B. D.; Kratzer, U.; Breithecker, K.; Koch, M. ACEA 1021, a Glycine Site Antagonist with Minor Psychotomimetic and Amnestic Effects in Rats. Eur. J. Pharmacol. 1997, 331, 109-116.
65. Morimoto, Y.; Wu, B.; Bart, R. D.; Morimoto, Y.; Pearlstein, R. D.; Warner, D. S. Effects of NMDA Receptor Glycine Recognition Site Antagonism on Cerebral Metabolic Rate for Glucose and Cerebral Blood Flow in the Conscious Rat. Brain Res. 1998, 779, 170-176.
66. Balster, R. L.; Mansbach, R. S.; Shelton, K. L. Behavioral Pharmacology of Two Novel Substituted Quinoxalinedione Glutamate Antagonists. Behav. Pharmacol. 1995, 6, 577-89.
67. Lutfy, K.; Weber, E. Attenuation of Nociceptive Responses by ACEA-1021, a Competitive NMDA Receptor/glycine Site Antagonist, in the Mice. Brain Res. 1996, 743, 17-23.
68. Brennan, T. J.; Zahn, P. K. Effect of Intrathecal ACEA-1021 in a Rat Model for Postoperative Pain. J. Pain. 2000, 1, 279-284.
69. Lutfy, K.; Doan, P.; Weber, E. ACEA-1328, a NMDA Receptor/glycine Site Antagonist, Acutely Potentiates Antinociception and Chronically Attenuates Tolerance Induced by Morphine. Pharmacol. Res. 1999, 40, 435-442.
70. Matsumoto, R. R.; Brackett, R. L.; Kanthasamy, A. G. Novel NMDA/glycine Site Antagonists Attenuate Cocaine-induced Behavioral Toxicity. Eur. J. Pharmacol. 1997, 338, 233-242.
71. Pouw, B.; Nour, M.; Matsumoto, R. R. Effects of AMPV/kainate Glutamate Receptor Antagonists on Cocaine-induced Convulsions and Lethality in Mice. Eur. J. Pharmacol. 1999, 386, 181-186.
72. Brackett, R. L.; Pouw, B.; Blyden, J. F.; Nour, M.; Matsumoto, R. R. Prevention of Cocaine-induced Convulsions and Lethality in Mice: Effectiveness of Targeting Different Sites on the NMDA Receptor Complex. Neuropharmacology 2000, 39, 407-418.
73. Albers, G. W.; Clark, W. M.; Atkinson, R. P.; Madden, K.; Data, J. L.; Whitehouse, M. J. Dose Escalation Study of the NMDA Glycine-site Antagonist Licostinel in Acute Ischemic Stroke. Stroke 1999, 30, 508-513.
74. N Receptor Antagonists. Drugs Fut. 1999, 24, 1107-1124.
75. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators. Phase II Studies of the Glycine Antagonist GV150526 in Acute Stroke, the North American Experience. Stroke 2000, 31, 358-365.
76. Dyker, A. G.; Lees, K. R. Safety and Tolerability of GV150526 (a Glycine Site Antagonist at the N-methyl-D-aspartate Receptor) in Patients with Acute Stroke. Stroke 1999, 30, 986-992.
77. Lees, K. R.; Asplund, K.; Carolei, A.; Davis, S. M.; Diener, H. C.; Kaste, M.; Orgogozo, J. M.; Whitehead, J. for GAIN International Investigators. Glycine Antagonist (Gavestinel) in Neuroprotection (GAIN International) in Patients with Acute Stroke: a Randomised. Controlled Trial. Lancet 2000, 355, 1949-1954.
78. Sacco, R. L.; DeRosa, J. T.; Haley, E. C. Jr.; Levin, B.; Ordronneau, P.; Phillips, S. J.; Rundek, T.; Snipes, R. G.; Thompson, J. L.; Glycine Antagonist in Neuroprotection Americas Investigators. Glycine Antagonist in Neuroprotection for Patients with Acute Stroke: GAIN Americas: a Randomized Controlled Trial. JAMA 2001, 285, 1719-1728.
79. Licostinel. Drugs R&D. 1999, 1, 27-28.
80. Stroke Therapy Academic industry Roundtable (STAIR), Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development. Stroke 1999, 30, 2752-2758.
81. Stroke Therapy Academic industry Roundtable II (STAIR II), Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies. Stroke 2001, 32, 1598-1606.
82. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N. Engl. J. Med. 1995, 333, 1581-1587.
83. Kwiatkowski, T. G.; Libman, R. B.; Frankel, M.; Tilley, B. C.; Morgenstern, L. B.; Lu, M.; Broderick, J. P.; Lewandowski, C. A.; Marler, J. R.; Levine, S. R.; Brott, T. Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N. Engl. J. Med. 1999, 340, 1781-1787.
84. Marler, J. R.; Tilley, B. C.; Lu, M.; Brott, T. G.; Lyden, P. C.; Grotta, J. C.; Broderick, J. P.; Levine, S. R.; Frankel, M. P.; Horowitz, S. H.; Haley, E. C. Jr.; Lewandowski, C. A.; Kwiatkowski, T. P. Early Stroke Treatment Associated with Better Outcome: the NINDS rt-PA Stroke Study. Neurology 2000, 55, 1649-1655.
85. Hacke, W.; Donnan, G.; Fieschi, C.; Kaste, M.; von Kummer, R.; Broderick, J. P.; Brott, T.; Frankel, M.; Grotta, J. C.; Haley, E. C. Jr.; Kwiatkowski, T.; Levine, S. R.; Lewandowski, C.; Lu, M.; Lyden, P.; Marler, J. R.; Patel, S.; Tilley, B. C.; Albers, G.; Bluhmki, E.; Wilhelm, M.; Hamilton, S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of Outcome with Early Stroke Treatment: Pooled Analysis of ATLANTIS, ECASS, and NINDS rt-PA Stroke Trials. Lancet 2004, 363, 768-774.
86. Tilley, B. C.; Lyden, P. D.; Brott, T. G.; Lu, M.; Levine, S. R.; Welch, K. M. Total Quality Improvement Method for Reduction of Delays between Emergency Department Admission and Treatment of Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Arch Neurol. 1997, 54, 1466-1474.
87. Haley, E. C. Jr.; Thompson, J. L.; Levin, B.; Davis, S.; Lees, K. R.; Pittman, J. G.; DeRosa, J. T.; Ordronneau, P.; Brown, D. L.; Sacco, R. L.; GAIN Americas and GAIN International Investigators. Gavestinel Does not Improve Outcome after Acute Intracerebral Hemorrhage: an Analysis from the GAIN International and GAIN Americas Studies. Stroke 2005, 36, 1006-1010.